Significant reduction of the incidence of ovarian hyperstimulation syndrome (OHSS) by using the LHRH antagonist Cetrorelix (Cetrotide®) in controlled ovarian stimulation for assisted reproduction

Archives of Gynecology and Obstetrics

Volumn 264, Issue 1, 2000, Pages 29-32

  Ludwig, M ^a   Felberbaum, R E ^a   Devroey, P ^b   Albano, C ^b   Riethmuller Winzen H ^c   Schuler A ^c   Engel, W ^c   Diedrich, K ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b CENTRE FOR REPRODUCTIVE MEDICINE   (Belgium)

^c ASTA MEDICA AG   (Germany)

Author keywords

Cetrorelix; LHRH antagonist; Ovarian hyperstimulation syndrome

Indexed keywords

BUSERELIN; CETRORELIX; CHORIONIC GONADOTROPIN; ESTRADIOL; GONADORELIN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; HUMAN MENOPAUSAL GONADOTROPIN;

AGE; ANAMNESIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; FERTILIZATION IN VITRO; HORMONE DETERMINATION; HUMAN; INFERTILITY; LUTEAL PHASE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OVARY FOLLICLE MATURATION; OVARY HYPERSTIMULATION; PREGNANCY RATE;

EID: 0033800494     PISSN: 09320067     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00007479     Document Type: Article

References (16)

1. Vascular endothelial growth factor plasma levels correlate to the clinical picture in severe ovarian hyperstimulation syndrome
2. Comparison of different doses of gonadotropin-releasing hormone antagonist cetrorelix during controlled ovarian hyperstimulation
3. Controlled ovarian stimulation with HMG: Results of a prospective randomized phase III European study comparing the LHRH-antagonist cetrorelix (cetrotide) and the LHRH-agonist buserelin
4. Ovarian hyperstimulation syndrome prediction by number of size of preovulatory ovarian follices
5. The pathophysiology of ovarian hyperstimulation syndrome - Views and ideas
6. Hormone profiles under ovarian stimulation with human menopausal gonadotropin (hMG) and concomitant administration of the gonadotropin releasing hormone (GnRH)-antagonist cetrorelix at different dosages
7. Uberblick uber das ovarielle uberstimulationssyndrom: Ein reproduktionsmedizinisch - Iatrogenes krankheitsbild mit internistischer konsequenz
8. Serum concentration of vascular endothelial growth factor cannot predict the course of severe ovarian hyperstimulation syndrome
9. Deep vein thrombosis during administration on HMG for ovarian stimulation
10. Myocardial infarction associated with ovarian hyperstimulation syndrome
11. In-vitro fertilization and the ovarian hyperstimulation syndrome
12. Risk factors and prognostic variables in the ovarian hyperstimulation syndrome
13. Human chorionic gonadotropin-dependent expression of vascular entothelial growth factor/vascular permeability factor in human granulosa cells: Importance in ovarian hyperstimulation syndrome
14. Complications of assisted reproductive techniques
15. Preventing severe ovarian hyperstimulation syndrome in an in vitro fertilization/embryo transfer program. Use of follicular aspiration after human chorionic gonadotropin administration